GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » YoY Rev. per Sh. Growth

Alphamab Oncology (STU:3NK) YoY Rev. per Sh. Growth : 454.55% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Alphamab Oncology YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Alphamab Oncology's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 was 454.55%.

Alphamab Oncology's Revenue per Share for the six months ended in Dec. 2024 was €0.06.

Alphamab Oncology YoY Rev. per Sh. Growth Historical Data

The historical data trend for Alphamab Oncology's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alphamab Oncology YoY Rev. per Sh. Growth Chart

Alphamab Oncology Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial - - 9.09 20.83 193.10

Alphamab Oncology Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.27 125.00 -31.25 27.78 454.55

Alphamab Oncology YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Alphamab Oncology's YoY Rev. per Sh. Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (A: Dec. 2024 )
=(Revenue per Share (A: Dec. 2024 )-Revenue per Share (A: Dec. 2023 ))/ | Revenue per Share (A: Dec. 2023 ) |
=(0.085-0.029)/ | 0.029 |
=193.10 %

Alphamab Oncology's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2024 )
=(Revenue per Share (Q: Dec. 2024 )-Revenue per Share (Q: Dec. 2023 )) / | Revenue per Share (Q: Dec. 2023 )) |
=(0.061-0.011)/ | 0.011 |
=454.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alphamab Oncology YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Alphamab Oncology's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Alphamab Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alphamab Oncology (STU:3NK) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
HKSE:02410 HKSE:02629 HKSE:00775 HKSE:02105 HKSE:02157 HKSE:02142 HKSE:01672 HKSE:02315 HKSE:02162 HKSE:02171 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
09966:Hong Kong
Address
No. 175 Fangzhou Road, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215127
Website
https://www.alphamabonc.com
Alphamab Oncology is a clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecifics and protein engineering. The company through its subsidiaries is engaged in the discovery, development manufacturing, and commercialization of biotherapeutics for cancer treatment. Its product pipeline includes various drug candidates such as KN035 (Envida), KN046, KN026, JSKN003, and KN019 among others in different stages of development.

Alphamab Oncology Headlines

No Headlines